TLDR Wall Street Zen downgraded PayPal stock from Buy to Hold, joining a cautious analyst consensus of 12 Buys, 27 Holds, and 4 Sells with an average price targetTLDR Wall Street Zen downgraded PayPal stock from Buy to Hold, joining a cautious analyst consensus of 12 Buys, 27 Holds, and 4 Sells with an average price target

PayPal (PYPL) Stock: Insiders Sell $2.4M in Shares as Price Targets Drop

2026/01/18 23:23
4 min read
For feedback or concerns regarding this content, please contact us at [email protected]

TLDR

  • Wall Street Zen downgraded PayPal stock from Buy to Hold, joining a cautious analyst consensus of 12 Buys, 27 Holds, and 4 Sells with an average price target of $76.05.
  • PayPal beat Q3 expectations with EPS of $1.34 versus $1.20 estimated and revenue of $8.42 billion versus $8.21 billion expected.
  • The stock opened at $56.89 on Friday, trading near its 12-month low of $55.85 and down from a 52-week high of $93.25.
  • Multiple analysts recently lowered price targets, including Stephens cutting from $75 to $65 and Robert W. Baird dropping from $83 to $66.
  • Company insiders sold approximately 36,156 shares worth $2.43 million over the last 90 days while the stock trades at under 10 times forward earnings.

PayPal closed Friday at $56.89, hovering just above its 12-month low of $55.85. The stock has dropped more than 20% over the past six months. Wall Street Zen downgraded the payment giant from Buy to Hold over the weekend, adding to a growing list of cautious calls from analysts.


PYPL Stock Card
PayPal Holdings, Inc., PYPL

The downgrade came despite PayPal beating third-quarter expectations in late October. The company reported earnings per share of $1.34, topping the consensus estimate of $1.20. Revenue reached $8.42 billion, exceeding the $8.21 billion analysts expected. Year-over-year revenue grew 7.3%.

PayPal set full-year 2025 guidance at $5.35 to $5.39 in earnings per share. Analysts expect the company to post $5.03 earnings per share for the current fiscal year. The company carries a market capitalization of $53.23 billion.

The analyst community remains split on PayPal’s prospects. Twelve analysts rate the stock a Buy while 27 assign it a Hold rating. Four analysts recommend selling. The average price target sits at $76.05, implying roughly 30% to 35% upside from current levels.

Royal Bank of Canada raised its price target from $88 to $91 in late October, maintaining an Outperform rating. Macquarie lifted its target from $95 to $100 the following day, also keeping an Outperform rating. Those bullish calls stand in contrast to recent cuts from other firms.

Stephens lowered its price target from $75 to $65 in mid-January, keeping an Equal Weight rating. Robert W. Baird dropped its target from $83 to $66 in December while maintaining a Neutral rating. Evercore ISI cut its target from $75 to $65 in early December with an In-line rating.

Valuation Gap Widens

PayPal now trades at a price-to-earnings ratio of 11.40 and a forward P/E under 10. The broader financial transaction services peer group commands roughly 21 times forward earnings. That discount reflects investor concerns about slowing growth and competitive pressures.

The company carries a debt-to-equity ratio of 0.56 with a current ratio of 1.34. Its 50-day moving average sits at $60.57 while the 200-day average rests at $66.82. The stock’s beta of 1.42 indicates higher volatility than the broader market.

Strategic Investments Face Scrutiny

Management is pushing into higher-margin products including buy-now-pay-later services and Venmo monetization. Buy-now-pay-later volumes are growing at over 20% quarterly. Internal projections suggest this product line could reach $40 billion in transaction volume during 2025 if adoption trends continue.

PayPal is also investing in what it calls “agentic commerce” through partnerships with OpenAI and Google. These initiatives aim to position the company at the intersection of AI-driven shopping and digital payments. The investments, however, require capital that could pressure operating margins in 2026.

Insider activity has tilted toward selling in recent months. Suzan Kereere sold 4,162 shares in November at an average price of $59.84, reducing her stake by 11.84%. Executive Vice President Diego Scotti sold 3,838 shares in late October at $68.97 per share, cutting his position by 18.43%. Over the past 90 days, insiders sold 36,156 shares worth approximately $2.43 million.

Institutional investors made several moves in the third quarter. Nordea Investment Management increased its position by 7.9% to 4.29 million shares valued at $291.3 million. Ariose Capital Management lifted its stake by 347% to 193,100 shares worth $12.9 million. Institutional investors and hedge funds own 68.32% of the company’s outstanding stock.

Analysts cite concerns about cooling consumer spending and rising competition as reasons for estimate revisions moving lower. The market is waiting for proof that new product initiatives can reignite revenue growth. The company must demonstrate its strategic investments will deliver durable acceleration before the stock receives a higher valuation multiple from investors.

The post PayPal (PYPL) Stock: Insiders Sell $2.4M in Shares as Price Targets Drop appeared first on CoinCentral.

Market Opportunity
Ucan fix life in1day Logo
Ucan fix life in1day Price(1)
$0.0004856
$0.0004856$0.0004856
-6.88%
USD
Ucan fix life in1day (1) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09